Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s New Guidelines On Foreign Investment Loosens Restrictions On Drug Distribution

This article was originally published in PharmAsia News

Executive Summary

A revised investment rule could open new opportunities in China’s enormous pharmaceutical distribution business. The sector, which has already embraced U.S. giant Cardinal Health and the UK’s Alliance Boots, is set for a major consolidation in coming years.

You may also be interested in...

China's Top Drug Distributors Are Soaring: China Earnings Round Up (Part 2)

SHANGHAI - China's drug distribution market and retail pharmacy revenue reached RMB 708 billion ($110.9 billion) in 2010, a 24.6% increase from 2009, and the top three drug distributors' market share increased by 5.8% to 26.7% through aggressive acquisitions to expand their distribution networks, according to China's Ministry of Commerce.

Alliance Boots Taps Retired Zuellig Pharma CEO to Lead Asia Operation, With M&A On The Mind

Major UK pharmaceutical and beauty products distributor Alliance Boots announced the appointment of retired Zuellig Pharma CEO Fritz Horlacher to head its heathcare division in Asia. The company aims to expand in Asia, especially in Thailand and Korea, which will pose a big challenge to Zuellig and other heavyweight pharmaceutical distributors

Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?

SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts